Get the Stockscreener App
6.18
2.49%
0.15
After Hours:
6.11
-0.07
-1.13%
Cybin Inc stock is traded at $6.18, with a volume of 434.53K.
It is up +2.49% in the last 24 hours and down -13.57% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$6.03
Open:
$6.05
24h Volume:
434.53K
Relative Volume:
0.54
Market Cap:
$155.66M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-29.75
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+10.55%
1M Performance:
-13.57%
6M Performance:
-23.70%
1Y Performance:
-39.71%
1-Day Range:
$6.05
$6.23
1-Week Range:
$5.61
$6.23
52-Week Range:
$4.81
$11.08
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.18 | 300.86M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Why Cybin Inc. stock could be next big winnerQuarterly Profit Report & Accurate Entry and Exit Point Alerts - moha.gov.vn
Cybin Announces Up to USD$35 Million At-The-Market Equity Program - Investing News Network
Cybin Secures $175 Million in Direct Offering to Advance Clinical Programs - MSN
Understanding Momentum Shifts in (CYBN) - news.stocktradersdaily.com
Will Cybin Inc. stock gain from government policiesJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges By GuruFocus - Investing.com Canada
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus
Canaccord Genuity Maintains Cybin (CYBN) Buy Recommendation - Nasdaq
Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT - GuruFocus
Canaccord Genuity lowers Cybin stock price target to $45 on dilution - Investing.com Australia
Canaccord Genuity lowers Cybin stock price target to $45 on dilution By Investing.com - Investing.com South Africa
Cybin price target lowered to $45 from $70 at Canaccord - TipRanks
Can Cybin Inc. stock deliver surprise earnings beatQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
What’s the recovery path for long term holders of Cybin Inc.Index Update & Consistent Growth Equity Picks - newser.com
Why Cybin Inc. Common Shares stock is a strong analyst pickEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Is Cybin Inc. Common Shares stock positioned for digital growth eraJuly 2025 Analyst Calls & Proven Capital Preservation Methods - newser.com
What market sentiment indicators show for Cybin Inc. Common Shares stockTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Can Cybin Inc. Common Shares stock sustain free cash flowWeekly Investment Report & AI Enhanced Trade Execution Alerts - newser.com
How reliable is Cybin Inc. (R7E) stock dividend growthGap Down & Long-Term Capital Growth Strategies - newser.com
Will Cybin Inc. Common Shares stock remain on Wall Street radarJuly 2025 Drop Watch & Low Drawdown Investment Strategies - newser.com
Will Cybin Inc. stock gain from strong economyStop Loss & Expert Verified Movement Alerts - newser.com
Price momentum metrics for Cybin Inc. explainedJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
How higher bond yields impact Cybin Inc. (R7E) stockJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Will Cybin Inc. (R7E) stock outperform foreign stocksTreasury Yields & Stepwise Trade Signal Guides - newser.com
Can technical indicators confirm Cybin Inc.’s reversalWeekly Stock Summary & Free Expert Verified Stock Movement Alerts - newser.com
Cybin Inc.: Strategic Positioning and Financial Strength Bolster Buy Rating - TipRanks
Is Cybin Inc. stock cheap at current valuationPortfolio Return Summary & AI Powered Trade Plan Recommendations - newser.com
Will Cybin Inc. (R7E) stock gain from green policiesTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Published on: 2025-11-19 00:19:18 - newser.com
Is Cybin Inc. stock oversold or undervaluedQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - newser.com
Long term hold vs stop loss in Cybin Inc.Weekly Loss Report & Safe Capital Growth Tips - newser.com
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Cap:
|
Volume (24h):